Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

99.79
-0.8200-0.82%
Post-market: 100.230.4350+0.44%16:52 EST
Volume:1.59M
Turnover:159.16M
Market Cap:19.29B
PE:-19.22
High:101.53
Open:100.60
Low:98.71
Close:100.61
52wk High:124.49
52wk Low:29.17
Shares:193.32M
Float Shares:165.00M
Volume Ratio:0.93
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1931
EPS(LYR):-3.5776
ROE:-60.76%
ROA:-32.29%
PB:12.08
PE(LYR):-27.89

Loading ...

Revolution Medicines Inc. updates financial calendar

Reuters
·
47 mins ago

A Look At Revolution Medicines (RVMD) Valuation After Strong One Year Shareholder Returns

Simply Wall St.
·
Yesterday

Royalty Pharma Q4 adjusted EBITDA beats analyst expectations

Reuters
·
Feb 11

Revolution Medicines put volume heavy and directionally bearish

TIPRANKS
·
Feb 03

Revolution Medicines Is Maintained at Overweight by JP Morgan

Dow Jones
·
Feb 03

Revolution Medicines Inc : JP Morgan Raises Target Price to $122.00 From $92.00

THOMSON REUTERS
·
Feb 02

Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Roche Holding AG (OtherRHHVF) and Incyte (INCY)

TIPRANKS
·
Jan 31

Revolution Medicines Inc : Raymond James Raises Target Price to $135 From $76

THOMSON REUTERS
·
Jan 30

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Neurocrine (NBIX)

TIPRANKS
·
Jan 30

Revolution Medicines Doses First Patient in Clinical Trial Evaluating Rmc-5127, a Ras(on) G12v-Selective Inhibitor

THOMSON REUTERS
·
Jan 29

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

GlobeNewswire
·
Jan 29

Analysts’ Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)

TIPRANKS
·
Jan 28

Revolution Medicines Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Jan 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $150 From $75

THOMSON REUTERS
·
Jan 27

Dow Gains Over 300 Points Ahead Of Key Earnings: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone

Benzinga
·
Jan 27

Top Midday Decliners

MT Newswires Live
·
Jan 27

Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach

TIPRANKS
·
Jan 27

Revolution Medicines Down Over 17%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies

Reuters
·
Jan 26

Revolution Medicines falls -19.7%

TIPRANKS
·
Jan 26